11C-Methionine-PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer

Molecular Imaging and Biology

Volumn 10, Issue 6, 2008, Pages 374-380

  Koizumi, Mitsuru ^a   Saga, Tsuneo ^a   Yoshikawa, Kyosan ^b   Suzuki, Kazutoshi ^a   Yamada, Shigeru ^b   Hasebe, Mitsuhiko ^b   Ohashi, Seiya ^b   Abd Elrazek, Sherif ^b   Ishikawa, Hiroyuki ^b   Sagou, Kenji ^b   Tamura, Katsumi ^b   Hara, Ryusuke ^b   Kato, Hirotoshi ^b   Yasuda, Shigeo ^b   Yanagi, Takeshi ^b   Tsujii, Hirohiko ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

C 11 methionine; Carbon ion radiotherapy; Positron emission tomography; Rectal cancer; Recurrence

Indexed keywords

METHIONINE C 11; CARBON; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; INTERMETHOD COMPARISON; ION THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; RECURRENCE RISK; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ADENOCARCINOMA; METHODOLOGY; MIDDLE AGED; PELVIS TUMOR; PROGNOSIS; RECTUM TUMOR; SCINTISCANNING; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; CARBON RADIOISOTOPES; FEMALE; HUMANS; MALE; METHIONINE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS;

EID: 53649110097     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0156-1     Document Type: Article

References (28)

1. Swedish Rectal Cancer Trial (1996) Local recurrence rate in randomized multicentre trial of pre-operative radiotherapy compared with surgery alone. Eur J Surg 162:397-402
2. Medical Research Council Rectal Cancer Working Party (1996) Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 348:1610-1614
3. Moriya Y (2006) Treatment strategy for locally recurrent rectal cancer. Jpn J Clin Oncol 36:127-131
4. Lowy AM, Rich TA, Skibber JM, Dubrow RA, Curley SA (1996) Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 223:177-185
5. Valentini V, Morganti AG, Gambacorta A et al (2006) Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiation Oncology Biol Phys 64:1129-1139
6. Tujii H, Mizoe J, Kamada T et al (2007) Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 48S:A1-A13
7. Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 26:1363-1378
8. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M (2003) Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44:1784-1788
9. Strauss LG, Klippel S, Pan L, Schonleben K, Haberkorn U, Dimitrakopoulou-Strauss A (2007) Assessment of quantitative FDG PET data in primary colorectal tumours: Which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging 34:868-877
10. Haberkorn U, Strauss LG, Dimitrakopoulou A et al (1991) PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 32:1485-1490
11. Ichiya Y, Kuwabara Y, Otsuka M et al (1991) Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32:1655-1660
12. Reinhardt M, Kubota K, Yamada S, Iwata R, Yaegashi H (1997) Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 38:290-297
13. Kubota K, Ishiwata K, Yamada S, Tada M, Sato T, Ido T (1991) Tracer feasibility for monitoring tumor radiotherapy: A quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32:2118-2123
14. Ogawa T, Kanno I, Shishido F et al (1991) Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32:197-202
15. Ogawa T, Shishido F, Kanno I et al (1993) Cerebral glioma: Evaluation with methionine PET. Radiol 186:45-53
16. Kubota K, Yamada S, Ishiwata K et al (1993) Evaluation of the treatment response of lung cancer with positron emission tomography and l-[methyl-11C]methionine: A preliminary study. Eur J Nucl Med 20:495-501
17. Zhang H, Yoshikawa K, Tamura K et al (2004) [11C] Methionine positron emission tomography and survival in patients with bone and soft tissue sarcoma treated by carbon ion radiotherapy. Clin Cancer Res 10:1764-1772
18. Anderson C, Koshy M, Staley C et al (2007) PET-CT fusion in radiation management of patients with anorectal tumors. Int J Rad Oncol Biol Phy 69:155-162
19. Kalff V, Duong C, Drummond EG, Matthews JP, Hicks RJ (2006) Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 47:14-22
20. Capiri C, Rubello D, Chierichetti F et al (2006) Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR 187:w202-w208
21. Wieder H, Otta K, Zimmermann F et al (2002) PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer. Eur J Nucl Med 29:789-796
22. Kanai T, Endo M, Minohara S et al (1999) Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int Radiat Oncol Biol Phys 44:201-210
23. Langstrom B, Antoni G, Gullberg P et al (1987) Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med 32:610-615
24. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L (2006) [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 27:1432-1437
25. Lindholm P, Leskinen-Kallio S, Grenman R et al (1995) Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [11C]methionine. Int J Radiat Oncol Biol Phys 32:787-794
26. Jansson T, Westin JE, Ahlstrom H, Lilia A, Langstrom B, Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470-1477
27. Pio BS, Park CK, Pietras R et al (2006) Usefulness 3¢-[F-18]fluoro-3¢-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36-42
28. HA, Geinitz H, Rosenberg R et al (2007) PET imaging with [F-18]3ô-deoxy-3ô-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 34:878-883